Hua Medicine (Shanghai) Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Hua Medicine (Shanghai).
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hua Medicine (Shanghai) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 109 | -263 | 400 | 404 | N/A |
| 3/31/2024 | 93 | -237 | 640 | 647 | N/A |
| 12/31/2023 | 77 | -211 | 880 | 889 | N/A |
| 9/30/2023 | 82 | -200 | 497 | 517 | N/A |
| 6/30/2023 | 88 | -189 | 115 | 145 | N/A |
| 3/31/2023 | 53 | -196 | -71 | -42 | N/A |
| 12/31/2022 | 18 | -204 | -258 | -230 | N/A |
| 9/30/2022 | 9 | -234 | -250 | -228 | N/A |
| 6/30/2022 | 0 | -265 | -243 | -225 | N/A |
| 3/31/2022 | 0 | -295 | -271 | -249 | N/A |
| 12/31/2021 | N/A | -326 | -300 | -273 | N/A |
| 9/30/2021 | 4 | -355 | -178 | -145 | N/A |
| 6/30/2021 | 9 | -385 | -56 | -18 | N/A |
| 3/31/2021 | 9 | -389 | -51 | -19 | N/A |
| 12/31/2020 | 9 | -393 | -47 | -21 | N/A |
| 9/30/2020 | 16 | -378 | -182 | -166 | N/A |
| 6/30/2020 | 23 | -363 | -318 | -311 | N/A |
| 3/31/2020 | 22 | -394 | -335 | -327 | N/A |
| 12/31/2019 | 22 | -425 | -352 | -342 | N/A |
| 9/30/2019 | 12 | -1,379 | -354 | -344 | N/A |
| 6/30/2019 | 3 | -2,333 | -356 | -347 | N/A |
| 3/31/2019 | 3 | -3,399 | -309 | -302 | N/A |
| 12/31/2018 | 9 | -3,603 | -275 | -269 | N/A |
| 9/30/2018 | 13 | -2,578 | -266 | -262 | N/A |
| 6/30/2018 | 17 | -1,554 | -257 | -255 | N/A |
| 3/31/2018 | 16 | -440 | N/A | -242 | N/A |
| 12/31/2017 | 11 | -273 | N/A | -199 | N/A |
| 12/31/2016 | 1 | -361 | N/A | -76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2552's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if 2552's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2552's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2552's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2552's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2552's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/23 05:57 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CLSA |
| Bo Li | CLSA |
| Ziyi Chen | Goldman Sachs |